| Co-Investigator(Kenkyū-buntansha) |
MORI Taisuke 国立研究開発法人国立がん研究センター, 中央病院, 医員 (00296708)
Sekine Shigeki 国立研究開発法人国立がん研究センター, 中央病院, 医長 (10321879)
HIRAOKA Nobuyoshi 国立研究開発法人国立がん研究センター, 中央病院, 科長 (40276217)
WATABE Yukio 東京歯科大学, レジデント (50733490)
IZUMO Toshiyuki 国立大学法人東京医科歯科大学, 准教授 (80322709)
下重 美紀 長崎大学, 医学部, 准教授 (00392340)
八木原 一博 埼玉県立がんセンター(臨床腫瘍研究所), その他部局等, 研究員 (00538126)
|
|---|
| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2015: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2014: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2013: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2011: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
|
|---|
| Outline of Final Research Achievements |
Molecular target therapy has gained attention among the therapeutic strategies for cancer. To identify novel molecular targets for tongue cancer, we performed a proteomic analysis of surgical specimens of tongue cancer using an antibody library consisting of the kinome.
We created a tissue microarray (TMA) comprising tongue cancer, and then we screened overexpressing kinase proteins in tongue cancer by antibody library. We identified kinase-X, which was overexpressed in the invasive front of the tongue cancer, but was not expressed at the normal mucosa of the tongue. Overexpression resulted from transfection of kinase-X to tongue cancer cells that showed increased cell motility. The increased cell motility was decreased by an administration of a small molecular inhibitor of kinase-X. Proliferation of cells transfected with kinase-X was decreased by the inhibition of kinase-X. We concluded that kinase-X has potential as a novel molecular target for squamous cell carcinoma of the tongue.
|
